8-K filing — Aclaris Therapeutics, Inc. (ACRS)
Filed: 2026-10-27 AccNo: 0001104659-26-119231 Size: 688 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Stocks · News reference
U.S. stock futures rise, Nasdaq 100 gains 200 points. Vipshop shares fall 4.9% after reporting Q2 earnings below expectations. Other stocks dip in pre-market trading.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Filed: 2026-10-27 AccNo: 0001104659-26-119231 Size: 688 KB Item 1.01: Entry into a Material Definitive Agreement Item 9.01: Financial Statements and Exhibits
Aclaris Therapeutics announces positive Phase 1b trial data for ATI-052 in eczema and asthma alongside a $50 million public financing round.
Aclaris Therapeutics announced the pricing of an underwritten public offering of common stock and pre-funded warrants expected to generate approximately $50 million in gross proceeds.
Aclaris Therapeutics announced positive primary analysis results from its Phase 1b proof-of-concept trial of ATI-052, a bispecific antibody targeting TSLP and IL-4Rα, in patients with atopic dermatitis and asthma.